Coagulation differences between healthy donors and DMT1 patients.

<p>(A) prothrombin time (PT) expressed as international normalized ratio (INR), (B) activated partial thromboplastin time (aPTT). DMSO was used as the vehicle control with a final concentration of 1% and heparin (indirect anticoagulant as the positive control) at a final concentration of 5 and...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Alejandro Carazo (2737303) (author)
مؤلفون آخرون:	Markéta Paclíková (21587193) (author), Jaka Fadraersada (21587196) (author), Raúl Alva-Gallegos (21587199) (author), Pavel Skořepa (21587202) (author), Catherine Gunaseelan (21587205) (author), Kateřina Matoušová (21587208) (author), Kristýna Mrštná (21587211) (author), Lenka Kujovská Krčmová (21587214) (author), Alena Šmahelová (21587217) (author), Vladimír Blaha (15856234) (author), Přemysl Mladěnka (2568289) (author)
منشور في:	2025
الموضوعات:	Biochemistry Cell Biology Science Policy Hematology Environmental Sciences not elsewhere classified Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified vitamin k levels dabigatran treatments resulted common biochemical parameters better lipid profile 1 &# 956 novel inflammatory markers four direct anticoagulants different direct anticoagulants observed coagulation differences dmt1 patients compared inflammatory markers direct anticoagulants prolonged coagulation coagulation brought blood coagulation active anticoagulants xlink "> tryptophan ratio treated samples rather associated prothrombotic state prothrombin time plasma treated paper suggests mentioned differences increased sensitivity healthy volunteers healthy individuals dmt1 group comparative studies analysis suggested also correlations 50 patients 001 ).
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Coagulation differences between healthy donors and DMT1 patients.

مواد مشابهة